Halozyme Therapeutics Approved for Listing on the American Stock Exchange
25 October 2004 - 11:01PM
PR Newswire (US)
Halozyme Therapeutics Approved for Listing on the American Stock
Exchange SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- Halozyme
Therapeutics, Inc. (OTC:HZYM) (BULLETIN BOARD: HZYM) , a
development stage biopharmaceutical company developing and
commercializing recombinant human enzymes, today announced that its
common stock has been approved for listing on the American Stock
Exchange ("Amex"). Halozyme's common stock is expected to commence
trading on the Amex under the symbol "HTI" on Monday, November 1,
2004. "We are very excited about moving to the American Stock
Exchange. It is indicative of the significant progress that
Halozyme has made over the past few months, including raising $13.9
million in a private placement, signing an exclusive sales and
marketing agreement with Baxter Healthcare for our drug product,
Enhanze SC(TM), and filing a 510(k) application for our medical
device, Cumulase(TM)," stated Jonathan Lim, MD, Halozyme's Chairman
and CEO. "Listing on the Amex will provide Halozyme's shareholders
with a desirable market structure and increased visibility in the
financial community." The approval of the listing of the common
stock on Amex is contingent upon Halozyme being in compliance with
all applicable listing standards on the date it begins trading on
the Amex, and may be rescinded if the Company is not in compliance
with such standards. Halozyme's hyaluronidase (rHuPH20) is a
recombinant form of the naturally occurring human enzyme and is
being investigated for its ability to break down hyaluronic acid
(HA), the space-filling "gel"-like substance that is a major
component of tissues throughout the body. Hyaluronidase that is
injected in the skin or in the muscle can temporarily digest the HA
gel to enhance the penetration and diffusion of other injected
drugs or fluids. About Halozyme Therapeutics, Inc. Halozyme
Therapeutics, Inc. is a development stage biopharmaceutical company
dedicated to developing and commercializing recombinant human
enzymes for the infertility (CUMULASE(TM)), ophthalmology (ENHANZE
SC(TM)), and oncology (CHEMOPHASE(TM)) communities. The company's
portfolio of products in development is based on intellectual
property covering the family of human enzymes known as
hyaluronidases. The first recombinant human hyaluronidase (rHuPH20)
is being developed by Halozyme as a medical device (CUMULASE(TM)),
drug enhancement agent (ENHANZE SC(TM)), and therapeutic biologic
(CHEMOPHASE(TM)). Safe Harbor Statement In addition to historical
information, the statements set forth above include forward-looking
statements (including, without limitation, statements concerning
the development and potential commercialization of its product
candidates, the commencement of trading on the American Stock
Exchange, the Company's visibility in the financial community and
the Company's compliance with the listing standards of the American
Stock Exchange) that involve risk and uncertainties that could
cause actual results to differ materially from those in the
forward-looking statements. The forward-looking statements are also
identified through use of the words "believe," "enable," "may,"
"will," "could," "intends," "estimate," "anticipate," "plan,"
"predict," "probable," "potential," "possible," "should,"
"continue," and other words of similar meaning. Actual results
could differ materially from the expectations contained in
forward-looking statements as a result of several factors,
including regulatory approval requirements and competitive
conditions. These and other factors that may result in differences
are discussed in greater detail in the company's reports on Forms
10-KSB, 10-QSB and other filings with the Securities and Exchange
Commission. DATASOURCE: Halozyme Therapeutics, Inc. CONTACT: David
A. Ramsay, Chief Financial Officer of Halozyme Therapeutics, Inc.,
+1-858-794-8889, ; or investors, Ina McGuinness, , or Bruce Voss,
both of Lippert/Heilshorn & Associates, +1-310-691-7100, for
Halozyme Therapeutics, Inc.; or media, Kathy Sweeney, ext. 230, ,
or Megan Riggs, ext. 200, , both of Mentus, +1-858-455-5500, for
Halozyme Therapeutics, Inc.
Copyright